These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24041357)

  • 1. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia.
    Wonder M; Backhouse ME; Hornby E
    Value Health; 2013; 16(6):1067-73. PubMed ID: 24041357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?
    Wonder M
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):465-7. PubMed ID: 24820934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delays in access to affordable medicines: putting policy into perspective.
    Pearce A; van Gool K; Haywood P; Haas M
    Aust Health Rev; 2012 Nov; 36(4):412-8. PubMed ID: 23062753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations.
    Tafuri G; Lucas I; Estevão S; Moseley J; d'Andon A; Bruehl H; Gajraj E; Garcia S; Hedberg N; Massari M; Molina A; Obach M; Osipenko L; Petavy F; Petschulies M; Pontes C; Russo P; Schiel A; Van de Casteele M; Zebedin-Brandl EM; Rasi G; Vamvakas S
    Br J Clin Pharmacol; 2018 May; 84(5):1013-1019. PubMed ID: 29370449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of health technology assessment bodies in shaping drug development.
    Ciani O; Jommi C
    Drug Des Devel Ther; 2014; 8():2273-81. PubMed ID: 25419117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
    Kim H; Byrnes J; Goodall S;
    Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.
    Tafuri G; Pagnini M; Moseley J; Massari M; Petavy F; Behring A; Catalan A; Gajraj E; Hedberg N; Obach M; Osipenko L; Russo P; Van De Casteele M; Zebedin EM; Rasi G; Vamvakas S
    Br J Clin Pharmacol; 2016 Oct; 82(4):965-73. PubMed ID: 27245362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
    Fischer KE; Heisser T; Stargardt T
    Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
    Maignen F; Osipenko L; Pinilla-Dominguez P; Crowe E
    Eur J Clin Pharmacol; 2017 Mar; 73(3):297-305. PubMed ID: 27942759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are Australians able to access new medicines on the pharmaceutical benefits scheme in a more or less timely manner? An analysis of pharmaceutical benefits advisory committee recommendations, 1999-2003.
    Wonder MJ; Neville AM; Parsons R
    Value Health; 2006; 9(4):205-12. PubMed ID: 16903989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Australian model of immunization advice and vaccine funding.
    Nolan TM
    Vaccine; 2010 Apr; 28 Suppl 1():A76-83. PubMed ID: 20413003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory scientific advice in drug development: does company size make a difference?
    Putzeist M; Mantel-Teeuwisse AK; Gispen-De Wied CC; Hoes AW; Leufkens HG
    Eur J Clin Pharmacol; 2011 Feb; 67(2):157-64. PubMed ID: 21049297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia.
    Phan YHL; De Abreu Lourenco R; Haas M; van der Linden N
    Mult Scler Relat Disord; 2018 Oct; 25():144-149. PubMed ID: 30077086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
    Wonder M; Dunlop S
    Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.